Skip to main content
OpenTrials
Completed

NCT Number: NCT07268976

Jackfruit Effects on Adipokines and Cognition in Boxers

This study investigates the effects of jackfruit oil extract on adipokine levels (Irisin, Omentin-1), brain-derived neurotrophic factor (BDNF), cognitive performance, and body measurements in healthy young boxers aged 18-25. Participants were randomly assigned to four groups receiving different doses of jackfruit oil extract (0, 100, 200, 300 mg/kg) or no supplement. Saliva samples, cognitive tests, and body measurements were collected at the start of the study and after 30 days to evaluate the outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bayburt Gençlik Merkezi Kapali Spor Salonu

Bayburt, Merkez, 69000, Turkey (Türkiye)

About this study

This interventional study evaluates the effects of different doses of jackfruit oil extract on healthy young boxers aged 18-25. Participants were randomly assigned to four groups and followed for 30 days.

Saliva samples were collected to measure irisin, omentin-1, and BDNF levels. Cognitive performance was assessed using the Wisconsin Card Sorting Test and the Trail Making Test. Anthropometric parameters including weight, BMI, waist, hip, chest, limb circumferences, and body composition were measured at baseline and on day 30.

Statistical analyses were performed using SPSS version 26. ANOVA, Duncan, and Pearson correlation tests were used to determine significant differences and relationships between variables.

This study is randomized and controlled. Participants receive either one of three doses of jackfruit oil extract or no supplement. The follow-up period is 30 days.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male boxers aged 18-25 years
  • Healthy individuals without any diagnosed chronic disease
  • Participating in regular weekly boxing training
  • Able to continue training throughout the study period
  • Willing to voluntarily participate in the study
  • Able to provide written and/or verbal informed consent

Exclusion criteria

  • Presence of chronic diseases (e.g., diabetes, cardiovascular disorders)
  • Any injury or musculoskeletal condition preventing continuation of training
  • Known allergy or hypersensitivity to jackfruit or its components
  • Use of medications or supplements that could interfere with study outcomes
  • Individuals who refuse to provide informed consent

Treatment and study plan

Jackfruit Supplement

Dietary Supplement

Participants in the experimental group will receive a daily dose of jackfruit supplement during the study period. The supplement is administered orally and standardized for bioactive components. Participants in the control group will not receive any jackfruit supplement.

Primary outcomes

  1. Salivary Irisin Level

    Time frame: Day 0 and Day 30

    Irisin levels measured from saliva samples collected from participants using the ELISA method.

  2. Salivary Omentin-1 Level

    Time frame: Day 0 and Day 30.

    Omentin-1 levels measured from saliva samples collected from participants using the ELISA method.

  3. Salivary BDNF Level

    Time frame: Day 0 and Day 30.

    BDNF levels measured from saliva samples collected from participants using the ELISA method.

Secondary outcomes

  1. Body Weight (kg)

    Time frame: Day 0 and Day 30

    Body weight measured using Tanita BC-418 bioimpedance device.

  2. Height (cm)

    Time frame: Day 0 and Day 30

    Height measured using a standard stadiometer.

  3. Body Mass Index (kg/m²)

    Time frame: Day 0 and Day 30

    BMI calculated using the formula weight (kg)/height (m²).

  4. Waist Circumference (cm)

    Time frame: Day 0 and Day 30

    Waist circumference measured with a flexible tape measure.

  5. Hip Circumference (cm)

    Time frame: Day 0 and Day 30

    Hip circumference measured with a flexible tape measure.

  6. Chest Circumference (cm)

    Time frame: Day 0 and Day 30

    Chest circumference measured using a flexible tape measure.

  7. Upper Arm Circumference (Right/Left, cm)

    Time frame: Day 0 and Day 30

    Right and left upper arm circumferences measured with a flexible tape measure.

  8. Wrist Circumference (Right/Left, cm)

    Time frame: Day 0 and Day 30

    Right and left wrist circumferences measured with a flexible tape measure.

  9. Thigh Circumference (Right/Left, cm)

    Time frame: Day 0 and Day 30

    Right and left thigh circumferences measured with a flexible tape measure.

  10. Calf Circumference (Right/Left, cm)

    Time frame: Day 0 and Day 30

    Right and left calf circumferences measured with a flexible tape measure.

  11. Total Body Fat Mass (kg)

    Time frame: Day 0 and Day 30

    Total body fat mass measured using Tanita BC-418.

  12. Total Body Fat Percentage (%)

    Time frame: Day 0 and Day 30

    Total body fat percentage measured using Tanita BC-418.

  13. Abdominal Fat Mass (kg)

    Time frame: Day 0 and Day 30

    Abdominal fat mass measured using Tanita BC-418.

  14. Regional Fat Percentages (Right/Left Arm & Leg)

    Time frame: Day 0 and Day 30

    Regional fat percentages for arms and legs measured by Tanita BC-418.

  15. Total Muscle Mass (kg)

    Time frame: Day 0 and Day 30

    Total muscle mass assessed using Tanita BC-418.

  16. Regional Muscle Mass (Right/Left Arm & Leg, kg)

    Time frame: Day 0 and Day 30

    Regional muscle mass of arms and legs measured by Tanita BC-418.

  17. Basal Metabolic Rate (BMR)

    Time frame: Day 0 and Day 30

    Basal metabolic rate calculated by Tanita BC-418.

  18. Metabolic Age

    Time frame: Day 0 and Day 30

    Metabolic age estimated using Tanita BC-418 device.

  19. Total Body Water (kg)

    Time frame: Day 0 and Day 30

    Total body water measured via bioimpedance analysis.

  20. Total Body Water Percentage (%)

    Time frame: Day 0 and Day 30

    Total Body Water Percentage (%)

  21. WCST Total Correct Responses

    Time frame: Day 0 and Day 30

    Total correct responses obtained from the Wisconsin Card Sorting Test.

  22. WCST Total Incorrect Responses

    Time frame: Day 0 and Day 30

    Total incorrect responses measured using the Wisconsin Card Sorting Test.

  23. WCST Perseverative Error Count

    Time frame: Day 0 and Day 30

    Perseverative errors recorded during the Wisconsin Card Sorting Test.

  24. WCST Total Time (seconds)

    Time frame: Day 0 and Day 30

    Total time required to complete the Wisconsin Card Sorting Test.

  25. Trail Making Test A Completion Time (seconds)

    Time frame: Day 0 and Day 30

    Completion time for Trail Making Test Part A.

  26. Trail Making Test B Completion Time (seconds)

    Time frame: Day 0 and Day 30

    Completion time for Trail Making Test Part B.

  27. Biomarker Correlations (Irisin-Omentin-BDNF vs. Dose/Day)

    Time frame: Based on Day 30 measurements

    Pearson correlation analysis examining relationships between biomarkers and intervention dose/day.

  28. Safety Outcomes (Adverse Event Monitoring)

    Time frame: Continuous monitoring throughout 30 days

    Monitoring of potential adverse events related to 300 mg/kg JOE administration.

Sponsors and collaborators

Lead sponsor

Bayburt University

Other

Registry information

Official study title

Effect of Jackfruit Consumption on Adipokine, Cerebral Response, Cognitive Performance and Anthropometric Parameters in Boxers

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 8, 2025
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.